Albion Financial Group UT trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 47.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,971 shares of the company’s stock after selling 22,007 shares during the quarter. Albion Financial Group UT’s holdings in AbbVie were worth $5,477,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Diversified Trust Co boosted its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new position in AbbVie during the 3rd quarter valued at $720,000. Railway Pension Investments Ltd boosted its stake in AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares in the last quarter. World Investment Advisors lifted its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co lifted its position in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares during the last quarter. 70.23% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ABBV has been the subject of a number of recent research reports. Guggenheim reiterated a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Evercore cut their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their target price for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.
AbbVie Stock Performance
Shares of NYSE:ABBV opened at $206.62 on Tuesday. The company has a market cap of $365.35 billion, a P/E ratio of 87.55, a P/E/G ratio of 0.73 and a beta of 0.38. The stock’s 50-day moving average is $221.30 and its 200-day moving average is $224.39. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the company earned $2.16 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.
Insider Activity
In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.
Key Headlines Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Analysts and outlets highlight AbbVie’s valuation and income appeal — calls that the shares look like a strong value play for long‑term investors given yield and discounted multiples. Here’s Why AbbVie (ABBV) is a Strong Value Stock
- Positive Sentiment: Seeking Alpha notes that while 2026 sets a high earnings bar, AbbVie’s shares remain attractive on valuation — a constructive view that can support the stock over time if guidance is met. AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
- Positive Sentiment: Comparisons with peers emphasize AbbVie’s attractive dividend profile versus Pfizer, supporting income‑focused demand for the stock. High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout
- Positive Sentiment: Analysts are watching Skyrizi and Rinvoq as the key growth drivers for Q1 immunology sales and market‑share recovery as Humira wanes — successful execution here would materially reinforce revenue trajectory. How Will Skyrizi and Rinvoq Shape AbbVie’s Q1 Immunology Sales?
- Neutral Sentiment: Sector news: two more drug firms are joining the TrumpRx pricing initiative — a broader pricing‑pressure story that could matter to big pharma if it expands, though the immediate impact on AbbVie is uncertain. Two more drug companies to officially launch on TrumpRx
- Neutral Sentiment: Miscellaneous industry piece (Regeneron/Kiniksa Arcalyst orphan‑drug coverage) is not AbbVie‑specific but contributes to wider sector investor interest in niche drug opportunities. Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
- Negative Sentiment: AbbVie lowered its Q1 and full‑year 2026 earnings outlook after taking a $744M R&D charge — a direct negative to near‑term earnings expectations and a primary reason for the share weakness. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
- Negative Sentiment: Market coverage notes the stock has underperformed peers and declined despite broader market gains — reinforcing short‑term selling pressure and investor caution. AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
- Negative Sentiment: Additional note on underperformance vs. competitors from MarketWatch — another datapoint traders use to justify reduced weight in the stock near term. AbbVie Inc. stock underperforms Monday when compared to competitors
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
